Marc Tessier-Lavigne

Marc Tessier-Lavigne
OC FRS FRSC FMedSci
Tessier-Lavigne in 2013
11th President of Stanford University
In office
September 1, 2016 – August 31, 2023
Preceded byJohn L. Hennessy
Succeeded byRichard Saller
10th President of Rockefeller University
In office
2011–2016
Preceded byPaul Nurse
Succeeded byRichard P. Lifton
Personal details
Born
Marc Trevor Tessier-Lavigne

(1959-12-18) December 18, 1959 (age 64)
Trenton, Ontario, Canada
NationalityCanada
United States
Children3
EducationMcGill University (BS)
New College, Oxford (BA)
University College London (PhD)
Scientific career
FieldsNeuroscience
InstitutionsUniversity of California, San Francisco
Genentech
Rockefeller University
Stanford University
Thesis Processing of Signals and Noise in the Outer Retina of the Salamander  (1987)
Doctoral advisorDavid Attwell
Other academic advisorsThomas Jessell

Marc Trevor Tessier-Lavigne OC FRS FRSC FMedSci (born December 18, 1959) is a Canadian-American neuroscientist who was the eleventh president of Stanford University.[1][2]

Previously, he was a professor at the University of California, San Francisco and then president of Rockefeller University in New York City. He was formerly executive vice president for research and chief scientific officer at Genentech.[3] As of 2021, he is on the boards of directors of Denali Therapeutics and Regeneron Pharmaceuticals, as well as the scientific advisory boards of Denali Therapeutics and Agios Pharmaceuticals.[4][5][6]

In 2022, the Stanford board of trustees opened an investigation into allegations that Tessier-Lavigne might have been involved in fabricating results in articles published between 2001 and 2008, when he was working at Genentech.[7][8][9][10][11] In July 2023, the trustees' report was released, finding that in several papers he co-authored "there was apparent manipulation of research data by others." Tessier-Lavigne then announced that he would be stepping down as president of Stanford, effective August 31, 2023.[12] On April 23, 2024, it was announced that Tessier-Lavigne would take the role of CEO of a new AI biotech drug discovery startup, Xaira Therapeutics.[13][14]

  1. ^ Lapin, Lisa (February 4, 2016). "Neuroscience pioneer Marc Tessier-Lavigne named Stanford's next president". Stanford University.
  2. ^ "Stanford's New President Announced". stanfordmag.org. February 4, 2016. Retrieved May 9, 2023.
  3. ^ Cite error: The named reference NYT was invoked but never defined (see the help page).
  4. ^ "Leadership". www.denalitherapeutics.com. Retrieved April 11, 2021.
  5. ^ "Meet Regeneron's Leadership Team". www.regeneron.com. Retrieved April 11, 2021.
  6. ^ "Agios". agios.com. Retrieved April 11, 2021.
  7. ^ Joseph, Andrew (November 30, 2022). "Stanford is investigating its president over allegations of research misconduct". STAT. Retrieved December 3, 2022.
  8. ^ Cite error: The named reference :1 was invoked but never defined (see the help page).
  9. ^ Cite error: The named reference Baker1 was invoked but never defined (see the help page).
  10. ^ Cite error: The named reference Baker2 was invoked but never defined (see the help page).
  11. ^ Baker, Theo (March 6, 2023). "'MTL knew': misconduct allegations independently corroborated in private correspondence to special committee". Stanford Daily. Retrieved March 6, 2023.
  12. ^ Saul, Stephanie (July 19, 2023). "Stanford President Will Resign After Report Found Flaws in His Research". The New York Times. ISSN 0362-4331. Retrieved July 19, 2023.
  13. ^ Leuty, Ron (April 23, 2024). "Backed by $1 billion, former Stanford President Marc Tessier-Lavigne heading AI-focused biotech startup". www.bizjournals.com.
  14. ^ Buvailo, Andrii. "A New Al Drug Discovery Startup Launched with $1 Billion in Capital". Archived from the original on April 23, 2024.